Haleon has been launched as an independent company focusing on consumer health, completing its demerger from GSK. The newly listed business is driven by its purpose to deliver better everyday health with humanity.

Trading commenced on the London Stock Exchange (LSE), with Brian McNamara, CEO, Haleon, leading the opening ceremony to signal the start of trading. Trading on the New York Stock Exchange (NYSE) is set to follow1, and a similar market-opening event will take place on July 20, 2022.

Haleon will continue to develop category-leading brands that address real consumer health need while focusing on future innovation across its entire portfolio.

The company expects to deliver medium-term annual organic revenue growth of 4-6 per cent. Despite huge improvements in medicine, data and technology, everyday health remains elusive for too many people. Haleon aims to change this through a two-pronged approach. First, by working to remove barriers to better everyday health, and second, by aiming to empower 50 million people a year by 2025 to be more included in opportunities for better everyday health.